Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.

Cold Spring Harbor molecular case studies - 1 May 2017

Purshouse Karin, Schuh Anna, Fairfax Benjamin P, Knight Sam, Antoniou Pavlos, Dreau Helene, Popitsch Niko, Gatter Kevin, Roberts Ian, Browning Lisa, Traill Zoe, Kerr David, Verrill Clare, Tuthill Mark, Taylor Jenny C, Protheroe Andrew

Abstract excerpt

Whole-genome sequencing (WGS) has transformed the understanding of the genetic drivers of cancer and is increasingly being used in cancer medicine to identify personalized therapies. Here we describe a case in which the application of WGS identified a tumoral BRCA2 deletion in a patient with aggressive dedifferentiated prostate cancer that was repeat-biopsied after disease progression. This would not have been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Share to Precision Medicine

Share to Prostatic Neoplasms

Share to Whole Genome Sequencing

Source

Open in PubMed Open full text

Identifiers

PMID: 28487881
DOI: 10.1101/mcs.a001362
PMCID: PMC5411692

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.PMID 28487881Read ↗

Comparison of whole genome sequencing with clinical targeted panel sequencing of metastatic prostate cancer: insights from real-world dataSemantic proximity Read ↗

Comparison of Whole Genome Sequencing with Clinical Targeted Panel Sequencing of Metastatic Prostate Cancer: Insights from Real- World DataSemantic proximity Read ↗

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Semantic proximity Read ↗

Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.Semantic proximity Read ↗

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.Semantic proximity Read ↗

Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.Semantic proximity Read ↗

Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer.Semantic proximity Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read ↗

Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.Semantic proximity Read ↗

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene MutationsSemantic proximity Read ↗

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable AlterationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.